Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

Targeting tumor's vulnerability yields durable responses in Phase I/II

Trial

SEATTLE, Nov. 21 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX), announced that cumulative preliminary results of a phase I trial combining cisplatin with brostallicin in patients with solid tumors that had relapsed or were resistant to front-line treatment were presented at the Highlights in Oncology meeting in Naples, Italy, on Tuesday, November 20, 2007. Cristina Geroni, Ph.D. of Nerviano Medical Sciences (NMS), which developed brostallicin, summarized the basis for the phase I trial design. The trial is based on data demonstrating tumors with high levels of GSH/GST, common in platinum-resistant disease, are more susceptible to the killing effects of brostallicin. High levels of GSH and GST are associated with resistance to most standard chemotherapy drugs

"Our phase I and II experience with brostallicin in over 160 patients demonstrates encouraging anti-tumor activity in a variety of solid tumors, with more than 50% of the patients experiencing at least disease stabilization," said Steven Weitman, M.D., of Systems Medicine.

The preliminary results from the first 21 patients treated in the phase I combination trial with cisplatin showed similar results, with 14 of the patients experiencing stable disease and half (50%) of those 14 patients having durable stable disease for more than six cycles of therapy. Toxicities were mainly hematological and were manageable and reversible in this heavily pretreated patient population. Phase II studies using this combination in patients resistant to standard therapy are planned.

About the Phase I Study

The phase I, multicenter, dose-escalation study of brostallicin in combination with cisplatin (cDDP) was conducted in patients with recurrent or metastatic solid tumors. Treatment cycles wer
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)..., , PARIS, November 27 /PRNewswire-Fi... approval to market Oralair(R) in both adults and ...ermany, the first country where,Oralair(R) has bee... Oralair(R) is now registered in Austria, Belg..., France, Germany, Greece, Hungary, Ireland, Italy...
(Date:11/25/2009)..., , BOSTON, Nov. 25 ...he H1N1 virus, genomic data from the 1918 pandemic... the current H1N1 pandemic, today issued its lates...shows that the lethality of the H1N1 ("Swine Flu")... during the virus,s current outbreak in the spring...
(Date:11/25/2009)..., , BEIJING, Nov. 25 /PRNewswi... developer and provider of vaccines, announced tod... to establish Sinovac (Dalian) Vaccine,Technology ...develop, produce,and commercialize human-use vacci...erience in developing and commercializing world-cl...
(Date:11/24/2009)..., , HOUSTON, Nov. 24 /PRNewswire-Firs... provider of electrical and communications systems...esidential markets, announced today that its comme...rom Manhattan Torcon JV to install the electrical ...lacement facility at the U.S. Army Medical Researc...
Breaking Biology Technology:STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2
...ealth Software Will be Core Application for M... Programs, WASHINGTON, Nov. 5 Netsmart Technolog...oftware and services for health and,human services...greement to,implement its public health software a...ent of Health and Wellness Promotion (DHWP). The,a...
...ients on TPI 287 show clinical benefit, BOULDER, ...daq: TPPH ) announced today financial results for...net loss for the third quarter of 2007 was $6.1 mi...loss for the third quarter of 2006 of,$3.6 million... the third,quarter of 2007 and 2006 is non-cash eq...
...ep closer to understanding the atomic forces that ...dy by researchers from the University of Pennsylva...ment of Energy,s Argonne National Laboratory. , T...ty of Pennsylvania, found a significant difference...d been coated with different isotopes of hydrogen ...
Other Biology Technology:Detroit Department of Health and Wellness Promotion Selects Netsmart Technologies Public Health Software 2Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 2Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 3Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 4Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 5Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 6Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 7Heavier hydrogen on the atomic scale reduces friction 2
(Date:11/24/2009)...at may help gut bacteria bind to the gastrointesti...producers to identify strains that are likely to b...o interact with cells lining the gut to have a ben...the gut they are more likely to stick around long ...Juge from the Institute of Food Research. IFR is ...
(Date:11/24/2009)...lass of ring-shaped protein motors has been uncove...onal Laboratory (Berkeley Lab) using a state-of-th...nced Light Source (ALS). These protein motors play... and are vital to the survival of all biological c...man papillomavirus, which has been linked to cervi...
(Date:11/24/2009)...09) -- The Wildlife Conservation Society (WCS) ann...ining population of Siberian tigers has likely dec...hing and habitat loss. , WCS says th...t needs to be done to protect remaining population... report was released by the Siberian Tiger Monitor...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Report shows dramatic decline in Siberian tigers 2TV bombards children with commercials for high fat and high sugar foods 10639 1TV bombards children with commercials for high fat and high sugar foods 10639 2TV bombards children with commercials for high fat and high sugar foods 10639 3Will New Anemia Drug Top Current Treatments 3F 60717 1Will New Anemia Drug Top Current Treatments 3F 60717 2Will New Anemia Drug Top Current Treatments 3F 60717 3New HPV Vaccine Might Stop Vulvar Cancer in its Tracks 60714 1New HPV Vaccine Might Stop Vulvar Cancer in its Tracks 60714 2New HPV Vaccine Might Stop Vulvar Cancer in its Tracks 60714 3
...n Americans have peripheral arterial disease (PAD)...ions include African-Americans (twice as likely to...cent develop PAD) and diabetics (one in three who ...a community health and public information programr...ne self-assessment quiz. , The online quiz ( www....
...Large flightless birds of the southern continents ...s, South American rheas and the New Zealand kiwi ...believed. , Instead, each species individually lo...did have the ability to fly, according to new rese...ology professor Edward Braun. , The new research,...
...belt , Dust is one of several types of aerosols ...orly understood ways. Dust scatters and absorbs so...also interact with cloud formation and other clima...l Lidar and Infrared Pathfinder Satellite Observat...ving understanding of how clouds and aerosols inte...
Other Biology News:At risk for peripheral arterial disease? Simple quiz provides key so you can circulate better 2At risk for peripheral arterial disease? Simple quiz provides key so you can circulate better 3New research challenges long-held assumptions of flightless bird evolution 2AGU journal highlights -- Sept. 3, 2008 2AGU journal highlights -- Sept. 3, 2008 3AGU journal highlights -- Sept. 3, 2008 4AGU journal highlights -- Sept. 3, 2008 5AGU journal highlights -- Sept. 3, 2008 6AGU journal highlights -- Sept. 3, 2008 7
...which belong to the transforming growth factor- (T...group of extra-cellular growth factors which contr...ion and tumor formation (1). Other members incude ...ntiation factors, AMH/MIS (Anti-Mullerian Hormone/...
...which belong to the transforming growth factor- (T...group of extra-cellular growth factors which contr...ion and tumor formation (1). Other members incude ...ntiation factors, AMH/MIS (Anti-Mullerian Hormone/...
...plating in just seconds , No need for glass rods...uniform spreading and more colonies, Two choices ...e for spreading 100 plates or single-use tubes for...ells on multiple plates simultaneously ,EZ-Sprea...
Silencer siRNA Starter Kit from Ambion
Biology Products: